ALNOV.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 11:35):

Stats
Today's Volume	123 527
Average Volume	195 682
Market Cap	51.13M
EPS	€0 ( 2024-04-24 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.720
ATR14	€0.00200 (0.28%)

Volume Correlation

Long: 0.04 (neutral)

Short: 0.73 (moderate)

Signal:(46.883) Neutral

Novacyt SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novacyt SA Correlation - Currency/Commodity

0.18
( neutral )

0.70
( moderate )

0.00
( neutral )

-0.34
( neutral )

Novacyt SA Financials

Annual	2022
Revenue:	€21.04M
Gross Profit:	€5.75M (27.31 %)
EPS:	€-0.310

FY	2022
Revenue:	€21.04M
Gross Profit:	€5.75M (27.31 %)
EPS:	€-0.310

FY	2021
Revenue:	€95.78M
Gross Profit:	€29.68M (30.99 %)
EPS:	€-0.122

FY	2020
Revenue:	€277.20M
Gross Profit:	€211.13M (76.16 %)
EPS:	€1.940

Financial Reports:

No articles found.

Novacyt SA Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Novacyt SA

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.